MENLO PARK, Calif.,
Aug. 9, 2018 /PRNewswire/
-- BioPharmX Corporation (NYSE American: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, today announced that the U.S. Patent and Trademark Office
has granted a fifth patent to the company – which means that three
of its drug delivery systems now have patent protection.
The patent, (U.S. Patent No. 10,034,899), entitled "Solid oral
dosage form for breast symptoms," protects improvements in
BioPharmX's novel system for the delivery of molecular iodine to
treat fibrocystic breast condition. It recognizes the unique
benefits provided by the addition of vitamins A and/or D and
calcium and/or iron to the company's Violet® iodine, a
novel and proprietary formulation for the treatment of fibrocystic
breast condition, containing iodide and iodate salts that react to
form molecular iodine when they are exposed to gastric
pH.
This is the third patent granted to BioPharmX this year. The
first, granted in February, was for the company's
microencapsulation delivery system. The second, granted in
March, protects the company's HyantX™ delivery system, which forms
the basis for two investigational drugs, BPX-01* for
acne and BPX-04* for rosacea.The company has another 31
patent applications pending, to protect all four of the BioPharmX
delivery systems.
"The patents granted to us by the USPTO validate the novelty of
our delivery systems," said R. Kehl
Sink, PhD, Senior VP of Intellectual Property and Legal at
BioPharmX. "These patents and the 31 pending patent applications
protect our investment in product innovation for years to
come."
Violet®, BioPharmX's first product, demonstrated that
the company could overcome barriers that have historically stumped
other pharmaceutical companies. This patent grant is another
milestone in BioPharmX's record of innovation.
About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a Silicon
Valley-based specialty pharmaceutical company, which seeks to
provide products through proprietary platform technologies for
prescription, over-the-counter (OTC), and supplement applications
in the health and wellness markets, including dermatology and
women's health. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statements
This press release contains forward-looking statements related to
the company's plans or developments that involve risks,
uncertainties and assumptions, and are subject to the "safe harbor"
of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words such as "plan," "expect,"
"believe," "intend," "should," "may" or similar expressions.
Important factors that could cause actual results to differ
materially than those expressed or implied in such statements
include, but are not limited to, the effect Violet may have for the
treatment of fibrocystic breast condition, the likelihood of being
granted additional patents, the company's ability to obtain and
enforce patent and other intellectual property rights and changes
in patent law in the United States
and internationally. Additional risks are set forth in the
company's filings with the Securities and Exchange Commission,
including those described in the company's Quarterly Report on Form
10-Q for the most recent fiscal quarter. The forward-looking
statements included in this news release are made only as of the
date hereof, and the company undertakes no obligation to publicly
update such statements.BioPharmX is a registered trademark of
BioPharmX, Inc.
* Caution: BPX-01 and BPX-04 are new drugs
limited by U.S. law to investigational use.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-announces-patent-award-expanding-protection-for-innovations-in-solid-dosage-forms-300693848.html
SOURCE BioPharmX Corporation